MYGNBullishMyriad Genetics expands SRL partnership to enable local BRACAnalysis testing in Japannews
Medium materiality5/10
Myriad Genetics Expands SRL Partnership in Japan to Support Future Growth
Nov 17, 2026, 9:38 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Localizing BRACAnalysis wet lab work could shorten turnaround times and reduce operational friction for Japanese patients and clinicians, supporting uptake and potential revenue growth if regulatory approvals and reimbursement are obtained; the impact depends on approval timing and reimbursement outcomes.
AI summary
What happened, with direct paths to the underlying reporting
Myriad expanded its collaboration with SRL to enable local BRACAnalysis testing in Japan (subject to regulatory approval); SRL will perform local lab wet work while Myriad retains interpretation and will seek additional approvals and reimbursement.
Myriad expanded its collaboration with SRL to enable local testing for BRACAnalysis® Diagnostic System in Japan, subject to regulatory approval.
Under the expanded agreement, SRL will perform all laboratory wet work locally in Japan while Myriad will continue to provide genetic interpretation services.
Local testing will eliminate the need to ship patient samples to Myriad’s central laboratory in Utah and is expected to shorten sample turn-around-time.
Myriad intends to pursue additional regulatory approvals and reimbursement in Japan to support broader precision medicine and companion diagnostic offerings.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
UnitedHealthcare ends coverage for MYGN GeneSight test effective H1 2025. Coverage loss may reduce revenue. 2024 GeneSight testing generated $45M, with commercial plans providing…
- Myriad Genetics reported Q1 revenue of $202.2 million, up 11.6% YoY. - EPS improved to -$0.01 from -$0.21 YoY, with a positive surprise. - Revenue breakdown shows mixed results…